A Study of the Safety and Efficacy Interferon-Gamma 1b in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Completed · Phase 3
Conditions studied: Idiopathic Pulmonary Fibrosis
In brief
Study GIPF-001 is phase 3 study designed to determine the safety and efficacy of IFN-g 1b administered by subcutaneous injection; compared to placebo in patients with IPF who are unresponsive to steroids. 330 patients have been enrolled and were assigned to either a IFN-g 1b group or a placebo group.
Key facts
- Study ID
- NCT00047645
- Run by
- InterMune
- People needed
- 330
- Starts
- 2000-04-01
- Expected to finish
- 2002-12-01
- Last updated by the study team
- 2007-11-02
Who can join
Age: 20 and older, up to 79. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Washington Medical Center — Seattle, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.